Teva Recalls Qnasl Nasal Aerosol Due to Content Uniformity Failure
Teva Pharmaceuticals is recalling Qnasl nasal aerosol canisters because the product failed stability testing for spray content uniformity.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which by definition is unlikely to cause adverse health consequences, fitting the 'Low' severity criteria for documentation or minor specification issues.
Plain-English summary
Teva Pharmaceuticals USA is recalling Qnasl (beclomethasone dipropionate) Nasal Aerosol 40 Mcg, 60 Metered Sprays. The recall involves 201,234 canisters distributed nationwide. The affected lots are 150096 (Exp. 3/2017) and 150327 (Exp. 10/2017), with NDCs 59310-206-06 and 59310-206-08. These are physician samples.
The recall was initiated because the product was out of specification for spray content uniformity during stability testing. This means the amount of medication in each spray may not be consistent.
Consumers and healthcare providers should stop using the affected product and contact their healthcare provider for guidance. The FDA has classified this as a Class III recall, indicating a remote possibility of adverse health consequences.
The recalled product
- Product
- Qnasl (beclomethasone dipropionate) Nasal Aerosol 40 Mcg, 60 Metered Sprays, Rx only, Manufactured for Teva Respiratory, LLC, Horsham, PA 19044, By: 3M Drug Delivery Systems, Northridge, CA 91324, NDC 59310-206-06 and 59310-206-08 (Physician Samples).
- Manufacturer
- Teva Pharmaceuticals USA
- Category
- Drug — Nasal Aerosol
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot #: 150096
- Exp. 3/2017
- Lot #: 150327
- Exp. 10/2017
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Teva Pharmaceuticals USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Teva Pharmaceuticals USA
See all →- ModerateDoxylamine Succinate and Pyridoxine Hydrochloride Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-02-09
- LowPrescription Drug Recall: Mimvey Mislabeling by Teva Pharmaceuticals
FDA (Drugs) · 2022-02-09
- ModerateTretinoin Capsules 10 mg Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2022-02-09
- LowMimvey Estradiol/Norethindrone Prescription Drug Mislabeling Recall
FDA (Drugs) · 2022-02-09
- ModerateBrinzolamide Ophthalmic Suspension recalled for defective container caps
FDA (Drugs) · 2022-01-26
Same hazard · content uniformity
See all →- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- HighOral contraceptive tablets recalled after failing content uniformity specifications
FDA (Drugs) · 2025-10-15
- HighCefixime Oral Suspension Recalled for Failed Content Uniformity Specifications
FDA (Drugs) · 2024-06-26
- SevereFDA Recalls Phenytoin Oral Suspension Due to Content Uniformity Failure
FDA (Drugs) · 2023-12-27
- ModerateDofetilide Capsules Recalled Due to Out-of-Specification Content Uniformity
FDA (Drugs) · 2023-08-16